Clinical Trial Detail

NCT ID NCT02695290
Title Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors Boehringer Ingelheim
Indications

lung non-small cell carcinoma

Therapies

Afatinib

Age Groups: adult

No variant requirements are available.